Generalized Anxiety Disorder

Recent advancements within the field of mental health with the use of psilocybin-assisted therapy, as well as Colorado’s forward-thinking legislation about this therapy, have proven exciting. Psilocybin-assisted therapy showcased promising results in treating Generalized Anxiety Disorder (GAD...

Mind Medicine (MindMed) (NASDAQ:MNMD) announced that the FDA has granted the "breakthrough therapy" designation to its MM120 (lysergide d-tartrate) program for the treatment of Generalized Anxiety Disorder (GAD).  The clinical-stage psychedelics biotech firm will now join industry counterparts...

Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.)  With variable symptoms, the condition typically involves a person suffering from excessive anxiety and worry for over six months, potentially causing...

Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The company also provided a corporate update and outlook for 2024. Clinical Development: Present...

Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has published new positive topline results from its Phase 2b study on a single dose of MM-120 (LSD tartrate,) with no additional therapeutic intervention, in Generalized Anxiety Disorder (GAD.)  MM-120 is the company...

MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering innovative treatments for brain health disorders, made a noteworthy announcement today. They have successfully concluded the enrollment and dosing phase of Study MMED008, a Phase 2b researching the...

MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed.  “We have seen a meaningful acceleration in enrollment over the last few months since our full set of study sites were...

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug CYB004. While the trial evaluates safety and efficacy of escalating doses of DMT and CYB004 in healthy...

Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions. Filament To Begin Phase 2 Study On Botanical Psilocybin Drug For Meth Use Disorder Clinical-stage natural psychedelic drug developer Filament Health Corp. (...

Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) has begun an investigative study on the dissociative effect of a proprietary and patent-pending formulation of (S)-ketamine, as well as an optimized...

Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ: IXHL) announced that its Phase 2 clinical trial assessing proprietary psilocybin-assisted psychotherapy for Generalized Anxiety Disorder (GAD) treatment achieved its...

Life sciences biotech company Cybin Inc. (NYSE: CYBN) announced its selection of the Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD) as the target indication for its proprietary deuterated DMT molecule, CYB004. Anxiety disorders are the most common mental health...

It’s the beginning of 2023 and psychedelics companies are updating the public on their developmental and clinical progress as well as their selected milestones for the year. Cybin’s Programs For MDD And Anxiety Disorders Cybin Inc. (NYSE: CYBN) outlined its near-term goals...

What a year for psychedelics! It feels like we’ve come a long way since the sector explode in 2019-2020, the launch of Benzinga's Psyched, companies’ massive migration from private to public, MAPS’ initiation of Phase 3 MDMA trials, the surge of the psilocybin wave,...

The clinical-stage biopharma company Mind Medicine -also known as MindMed (NASDAQ: MNMD), which recently made headlines regarding its stock, announced it will begin dosing patients within its Phase 2b trial on LSD compound, MM-120, for the treatment of Generalized Anxiety Disorder (GAD)....